Pharmacovigilance vs Clinical Safety: Understanding the Key Differences in Drug Development

In clinical research, pharmacovigilance and clinical safety are closely connected.

So closely, in fact, that the terms are sometimes used as though they mean exactly the same thing.

They do not.

Both ultimately contribute to the same fundamental objective:

Protecting participants and patients by understanding and managing the risks associated with medicines.

But they differ in scope, timing, data sources and operational responsibilities.

For sponsors, CROs, investigators and clinical research professionals, understanding this distinction is more than terminology.

It affects how safety teams are structured, how responsibilities are assigned, how information flows across a development programme and how emerging risks are identified and managed.

Start With the Bigger Concept: What Is Pharmacovigilance?

The World Health Organization defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or other medicine-related problems.

This definition immediately tells us something important:

Pharmacovigilance is not simply adverse-event reporting.

It is a medicine-lifecycle discipline.

It may encompass safety information arising during:

Pre-authorisation clinical development

↓

Regulatory review

↓

Post-authorisation use

↓

Long-term surveillance

The objective is to understand how the safety profile of a medicinal product evolves as exposure increases and new information becomes available.

What Do We Mean by Clinical Safety?

In drug development, clinical safety generally refers to the activities used to collect, assess, monitor and interpret safety information arising during clinical development.

That can include:

• Adverse Events (AEs)
• Serious Adverse Events (SAEs)
• Suspected adverse reactions
• SUSARs
• Laboratory abnormalities
• Vital-sign abnormalities
• ECG findings
• Physical examination findings
• Adverse Events of Special Interest (AESIs)
• Dose-limiting toxicities
• Pregnancy information
• Safety endpoints
• Deaths and discontinuations
• Other clinically relevant safety observations

Clinical safety therefore focuses heavily on answering:

“What are we learning about the safety of this investigational product in the participants exposed during clinical development?”

Pharmacovigilance asks that question too-but across a broader product lifecycle.

The Simplest Way to Understand the Difference

A useful conceptual distinction is:

Clinical Safety

Safety surveillance within clinical development.

Pharmacovigilance

The broader system for understanding and managing medicinal-product safety across development and post-authorisation use.

There is substantial overlap.

Clinical safety can therefore be considered an important component of the broader pharmacovigilance framework.

But organizational terminology varies between companies, so the exact boundaries of departments labelled “Clinical Safety,” “Drug Safety” or “Pharmacovigilance” are not universally standardized.

That is why responsibilities should be defined explicitly rather than assumed from job titles.

Consider a Medicine Across Its Lifecycle

Imagine an investigational medicine entering first-in-human development.

During early clinical trials, safety teams may examine:

• Initial tolerability
• Dose-related toxicity
• Laboratory changes
• Serious events
• Potential target-organ toxicity

As development progresses, exposure increases.

The safety questions evolve.

Phase II and III programmes may examine:

• Larger safety datasets
• Adverse-event patterns
• Events of special interest
• Treatment discontinuations
• Comparator differences
• Subgroup effects
• Cumulative safety experience

After authorization, the medicine may be used by thousands-or millions-of patients.

Now additional evidence may emerge from:

• Spontaneous adverse-reaction reports
• Real-world healthcare databases
• Registries
• Scientific literature
• Post-authorisation studies
• Other regulatory authorities
• Medication-error reports
• Special populations
• Long-term exposure

The safety function therefore evolves from:

Clinical-trial safety surveillance

into

Lifecycle pharmacovigilance.

Clinical Safety Begins With the Participant

During a clinical trial, the investigative site is often the first point at which new safety information becomes visible.

A participant develops a medical event.

The investigator assesses it.

Depending on the event and applicable requirements, information may then move through a pathway such as:

Participant

↓

Investigator / Site

↓

Sponsor or CRO Safety Team

↓

Safety Database

↓

Medical Review

↓

Regulatory Assessment

↓

Required Reporting

↓

Cumulative Safety Evaluation

This process requires close interaction between:

• Investigators
• CRCs
• CRAs
• Project teams
• Medical monitors
• Safety physicians
• Pharmacovigilance specialists
• Data managers
• Regulatory teams

Clinical safety is therefore inherently cross-functional.

AE, SAE and SUSAR Are Not Interchangeable

Understanding the terminology is fundamental.

Adverse Event — AE

An adverse event is an untoward medical occurrence associated temporally with use of a medicinal product, without necessarily implying causation.

Therefore:

AE ≠ adverse reaction

An event may occur while a participant is receiving treatment without being caused by that treatment.

Serious Adverse Event — SAE

Seriousness relates to regulatory outcome criteria.

An event may be considered serious when, for example, it:

• Results in death
• Is life-threatening
• Requires or prolongs inpatient hospitalization
• Results in significant disability/incapacity
• Results in congenital anomaly/birth defect

Other medically important events may also meet seriousness criteria depending on the circumstances.

Importantly:

Seriousness ≠ severity.

A severe event is not automatically serious in the regulatory sense.

SUSAR

A Suspected Unexpected Serious Adverse Reaction combines three important assessments:

• Serious
• Suspected causal relationship
• Unexpected

SUSARs may trigger expedited regulatory reporting according to applicable jurisdictional requirements.

ICH E2A provides internationally harmonized definitions and standards for expedited reporting during clinical development.

Case Processing Is Only One Part of Safety

A pharmacovigilance operation may process thousands of Individual Case Safety Reports.

Each case may involve:

Receipt → Triage → Data Entry → Coding → Medical Assessment → Expectedness → Causality → Quality Control → Submission → Follow-up

These activities are essential.

But a compliant case-processing system alone does not constitute mature pharmacovigilance.

Why?

Because an individual case tells us what happened to one person.

Safety science also needs to ask:

What do all the cases tell us together?

Aggregate Safety Assessment Changes the Perspective

Imagine five serious cardiac events occurring across a global development programme.

Individually, none may establish causality.

But when reviewed together, important questions emerge:

• Are the events occurring more frequently than expected?
• Are they concentrated in one treatment arm?
• Is there a temporal relationship with exposure?
• Is there a dose relationship?
• Are particular patients at greater risk?
• Is there biological plausibility?
• Are similar findings appearing in other studies?

FDA's current IND safety-reporting framework specifically emphasizes sponsor evaluation of safety information and recognizes situations in which aggregate analysis is necessary to determine whether evidence suggests a causal relationship.

This is where pharmacovigilance moves beyond individual case management into safety science.

Signal Detection: Looking for the Pattern

A safety signal is information suggesting a new potentially causal association—or a new aspect of a known association—that warrants further investigation.

Signals may arise from:

• Individual cases
• Clusters of cases
• Clinical trials
• Laboratory trends
• Scientific literature
• Nonclinical findings
• Real-world data
• Spontaneous reporting systems
• Other regulatory information

The crucial word is:

Signal.

A signal is not automatically proof of causality.

It is information that requires evaluation.

Signal management may involve:

Detection

↓

Validation

↓

Prioritization

↓

Assessment

↓

Recommendation

↓

Risk-management action where appropriate

This illustrates why pharmacovigilance requires medical, epidemiological and scientific judgment—not merely database management.

Where Does the Medical Monitor Fit?

Another source of confusion is the relationship between pharmacovigilance and medical monitoring.

The medical monitor may support:

• Clinical interpretation of adverse events
• Protocol-related medical questions
• Eligibility questions
• Review of laboratory abnormalities
• Emerging medical issues
• Safety trend assessment
• Investigator communication
• Escalation of safety concerns

The PV/safety organization may manage:

• Safety case processing
• Regulatory reporting
• Safety database activities
• Aggregate safety review
• Signal-management processes
• Safety documentation

The functions overlap, but they are not necessarily identical.

The exact operating model varies between sponsors and CROs.

The important requirement is not what the departments are called.

It is that responsibilities, interfaces and escalation pathways are clearly defined.

Clinical Database vs Safety Database

Another important distinction exists at the system level.

Clinical trial information may be captured in the:

EDC system

while SAE information may also be captured in the:

Safety database

This creates two related records of the same event.

For example:

EDC

Participant 004
Hospitalization
Onset: 12 March

Safety Database

Participant 004
Serious adverse event
Onset: 13 March

Now there is a discrepancy.

Which date is correct?

This is why SAE reconciliation is important.

Clinical data management and safety teams need processes to identify and resolve inconsistencies between clinical and safety systems.

Safety cannot operate as an isolated department.

Expectedness Is Not the Same as Predictability

Expectedness is assessed against the applicable reference safety information.

During clinical development, that may involve the Investigator's Brochure and defined Reference Safety Information.

A reaction is not “expected” simply because a physician thinks:

“This could happen with this type of drug.”

The assessment must follow the applicable reference information and regulatory framework.

This distinction directly affects expedited reporting.

Safety Reporting Is Jurisdiction-Specific

Global pharmacovigilance becomes particularly complex because safety-reporting requirements are not identical everywhere.

Under the U.S. IND framework, sponsors must notify FDA and participating investigators of qualifying potential serious risks within applicable reporting timelines. FDA's December 2025 final sponsor guidance also addresses safety surveillance plans, aggregate analysis and other aspects of IND safety assessment.

European clinical trials operate under the EU Clinical Trials Regulation and associated safety-reporting requirements.

Other countries may impose additional national requirements.

A global safety operation therefore needs:

A harmonized core process + jurisdiction-specific regulatory intelligence.

Pharmacovigilance Continues After Approval

This is where the difference becomes particularly clear.

The clinical trial eventually ends.

Pharmacovigilance does not.

Once a medicine reaches routine clinical use, safety surveillance may involve:

• Spontaneous adverse-reaction reporting
• Signal management
• Periodic safety reports
• Risk Management Plans
• Post-authorisation safety studies
• Literature surveillance
• Regulatory commitments
• Real-world evidence
• Risk-minimization measures

The patient population also becomes broader than the population studied before authorization.

Rare and long-latency risks may become more apparent only after substantially greater exposure.

Pharmacovigilance therefore follows the medicine beyond the clinical development programme.

The Difference in One View

The boundaries can vary organizationally, but the conceptual difference remains useful.

What Sponsors Need to Get Right

Whether activities are performed internally or outsourced to a CRO or specialist PV provider, sponsors need clarity around:

Who receives safety information?

Who performs medical review?

Who assesses expectedness?

Who determines reportability?

Who submits regulatory reports?

Who performs reconciliation?

Who reviews aggregate safety?

Who evaluates signals?

Who communicates emerging risks?

Who maintains oversight of vendors?

Ambiguity at these interfaces can create both safety and compliance risk.

Outsourcing Safety Does Not Mean Outsourcing Accountability

Many sponsors rely on CROs and specialist pharmacovigilance providers.

This may be entirely appropriate.

But outsourcing requires clear governance.

Sponsors should understand:

• Which activities have been transferred
• Which activities remain internal
• How safety information moves between organizations
• How timelines are monitored
• How cases are reconciled
• How emerging signals are escalated
• How vendor performance is reviewed

A safety database can be hosted externally.

Case processing can be outsourced.

Operational activities can be delegated.

Sponsor oversight still matters.

The Agile Clinical Trendz Perspective

At Agile Clinical Trendz, we view clinical safety and pharmacovigilance as connected components of an integrated safety framework.

Effective safety oversight requires coordination across:

Sites

Clinical Operations

Medical Monitoring

Pharmacovigilance

Data Management

Biostatistics

Regulatory Affairs

Quality

The objective should never simply be:

“Process the case.”

It should be:

“Understand what the case contributes to the evolving safety profile of the product.”

Clinical safety helps us understand what is happening to participants during development.

Pharmacovigilance extends that responsibility across the medicine lifecycle.

And both ultimately serve the same purpose:

Turning safety information into decisions that protect patients.

References

1. World Health Organization. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. WHO; 2002.
2. International Council for Harmonisation. ICH E2A: Clinical Safety Data Management-Definitions and Standards for Expedited Reporting. 1994.
3. International Council for Harmonisation. ICH E2F: Development Safety Update Report. 2010.
4. International Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical Practice. 2025.
5. U.S. Food and Drug Administration. Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies. Final Guidance. December 2025.
6. U.S. Food and Drug Administration. Investigator Responsibilities—Safety Reporting for Investigational Drugs and Devices. Final Guidance. December 2025.
7. European Medicines Agency. Reporting Safety Information on Clinical Trials. Current guidance.